Surprisingly, we also noted in the Labrecque et al. 2019 dataset an increased DPYSL5 expression in two double- negative (AR and NE negative) prostate cancer transition stage tumors that can potentially give rise to  NEPC tumors over time33. Here, DPYSL5 is linked to prostate carcinoma.